Hosted on MSN11h
HC Wainwright & Co. Initiates Coverage of Knightscope (KSCP) with Buy Recommendation
Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Knightscope (NasdaqCM:KSCP) with a Buy ...
H.C. Wainwright Remains a Buy on Neptune Digital Assets (NDA)
In a report released today, Kevin Dede from H.C. Wainwright maintained a Buy rating on Neptune Digital Assets (NDA – Research Report), with a ...
Fintel on MSN17h
HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation
Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Surrozen (NasdaqCM:SRZN) with a Buy ...
H.C. Wainwright Remains a Buy on Bioxcel Therapeutics (BTAI)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) yesterday and set a price target ...
HC Wainwright Reiterates “Buy” Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...
HC Wainwright Has Optimistic Outlook of ATRA Q3 Earnings
HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a report released on Tuesday, ...
Investing15d
H.C. Wainwright reiterates TG Therapeutics stock buy rating on growth
On Wednesday, H.C. Wainwright reaffirmed a Buy rating on shares of TG Therapeutics (NASDAQ:TGTX) shares with a steady price target of $55.00. The firm's analyst highlighted the company's strong ...
Investing16d
H.C. Wainwright optimistic on Akebia shares despite risks to commercial opportunity
On Tuesday, H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) stock with a steady price target of $7.50, significantly above the current trading price of $1.88. The firm's ...